Clinical trial
Phenoxodiol in Treating Patients With Refractory Solid Tumors
NCT00022295 · Kazia Therapeutics Limited, Industry · Completed
Key facts
| NCT number | NCT00022295 |
|---|---|
| Title | Phenoxodiol in Treating Patients With Refractory Solid Tumors |
| Official title | Phase IB Study of Phenoxodiol Given by Constant Intravenous Infusion in Patients With Solid Neoplasms (With the Exception of Breast Cancer) Whose Tumors Are Refractory to Standard Therapy |
| Lead sponsor | Kazia Therapeutics Limited, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | idronoxil |
| Enrollment | 36 |
| Start date | Aug 1, 2001 |
| Completion | Oct 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: